An early study demonstrated that after a short follow-up of 11.4 days, patients with severe COVID-19 displayed a decrease in the earliest plasma GFAP peak, whilst NfL showed a sustained increase [2], perhaps reflecting a sequence of early astrocytic response and more delayed axonal injury. This evidence concerns the gene GFAP and COVID-19.